Stockscreener 앱 받기
5.22
4.19%
0.21
시간 외 거래:
5.22
전일 마감가:
$5.01
열려 있는:
$5.04
하루 거래량:
1.92M
Relative Volume:
0.80
시가총액:
$769.98M
수익:
$204.73M
순이익/손실:
$-184.29M
주가수익비율:
-7.2239
EPS:
-0.7226
순현금흐름:
$-51.87M
1주 성능:
+2.76%
1개월 성능:
+25.78%
6개월 성능:
+50.87%
1년 성능:
+149.76%
1일 변동 폭
$5.03
$5.315
1주일 범위
$4.8514
$5.315
52주 변동 폭
$1.99
$5.315
마라바이 라이프 Stock (MRVI) Company Profile
명칭
Maravai Lifesciences Holdings Inc
전화
(858) 546-0004
주소
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
5.22 | 731.63M | 204.73M | -184.29M | -51.87M | -0.7226 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
마라바이 라이프 Stock (MRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | 개시 | Guggenheim | Neutral |
| 2024-12-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-08 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-08-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | 개시 | Craig Hallum | Buy |
| 2023-12-12 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-08-08 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-01-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2022-11-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2020-12-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 개시 | Credit Suisse | Outperform |
| 2020-12-15 | 개시 | Goldman | Buy |
| 2020-12-15 | 개시 | Jefferies | Buy |
| 2020-12-15 | 개시 | Robert W. Baird | Outperform |
| 2020-12-15 | 개시 | Stifel | Buy |
| 2020-12-15 | 개시 | William Blair | Outperform |
| 2020-12-14 | 개시 | UBS | Buy |
모두보기
마라바이 라이프 주식(MRVI)의 최신 뉴스
Maravai LifeSciences Holdings, Inc. (MRVI) tops Q1 earnings and revenue estimates - MSN
Insider Sell: Kurt Oreshack Sells 50,000 Shares of Maravai LifeS - GuruFocus
Maravai LifeSciences general counsel Oreshack sells $253,999 shares - Investing.com
Maravai Lifesciences Holdings Insider Sold Shares Worth $254,000, According to a Recent SEC Filing - Moomoo
MRVI (MRVI) CEO Brust reports 351,001-share tax withholding, holds 2.1M shares - Stock Titan
Maravai (NASDAQ: MRVI) General Counsel sells 50,000 shares under 10b5-1 plan - Stock Titan
Maravai Lifesciences director gifts 92,586 shares | MRVI Insider Trading - Stock Titan
Kurt Oreshack notifies sale of 25,000 MRVI Class A shares (NASDAQ: MRVI) - Stock Titan
Maravai (MRVI) brokered sale notice: 25,000 Class A shares via Fidelity - Stock Titan
Maravai LifeSciences refinances debt with $180M credit facilities; lowers outstanding borrowings - MSN
Maravai LifeSciences Projects Strong Annual Revenue and Trims Q1 Net Loss - HarianBasis.co
This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio - Yahoo Finance
MRVI Technical Analysis & Stock Price Forecast - Intellectia AI
MRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Investors’ Stock Portfolio: Top 10 Penny Stocks To Buy - Insider Monkey
Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025MRVI - ACCESS Newswire
Maravai LifeSciences refinances debt, cuts principal by $92.9M - Investing.com UK
Maravai LifeSciences (MRVI) Secures New $150M Credit Facility - GuruFocus
Maravai LifeSciences refinances debt, cuts principal by $92.9M By Investing.com - Investing.com Australia
Maravai LifeSciences Refinances Debt, Extends Credit Facilities - TipRanks
Maravai LifeSciences Refinances Credit Agreement, Extends Maturity to 2032 - Moomoo
Maravai LifeSciences (NASDAQ: MRVI) cuts debt and extends loan maturity to 2032 - Stock Titan
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032 - Business Wire
Maravai Stock Dips Monday With Eyes on Major Event This Week - Bez Kabli
Maravai LifeSciences Holdings, Inc. 8-K Filing Details for May 26, 2026: Company Information, Stock, and Regulatory Compliance - Minichart
Maravai Lifesciences Shareholders Back Board, Pay, Auditor - TipRanks
Maravai LifeSciences (MRVI) shareholders approve directors, auditor and pay at 2026 meeting - Stock Titan
All you need to know about Maravai LifeSciences (MRVI) rating upgrade to buy - MSN
Maravai (MRVI) director granted 46,293 restricted stock units - Stock Titan
Maravai LifeSciences (MRVI) Surges Over 6% as Biotech Sector Shows Signs of LifeRisk Parity Rebalance - thelegaladvocate.com
Director-linked entity at Maravai (NASDAQ: MRVI) awarded 46,293 RSUs - Stock Titan
Maravai (MRVI) director Susannah Gray receives 46,293-share stock unit award - Stock Titan
Maravai (MRVI) director Mihas receives 46,293 RSUs held for GTCR-affiliated entity - Stock Titan
Maravai LifeSciences (MRVI) director receives 46,293-share RSU award - Stock Titan
[Form 4] MARAVAI LIFESCIENCES HOLDINGS, INC. Insider Trading Activity - Stock Titan
RSU grant to GTCR-affiliated entity via Maravai (MRVI) director - Stock Titan
Maravai (MRVI) director awarded 46,293 RSUs in equity grant - Stock Titan
Maravai LifeSciences (MRVI) Holds Tight Near Support Amid Minimal Price MovementIntraday Profile - thelegaladvocate.com
Earnings Preview: MRVI to Report Financial Results Post-market on February 25 - Moomoo
Maravai (MRVI) officer granted 5,006 ESPP shares at $1.79 - Stock Titan
Maravai Lifesciences (NASDAQ: MRVI) counsel gets 776 ESPP shares - Stock Titan
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference - Business Wire
Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI) - Seeking Alpha
Maravai LifeSciences Holdings, Inc.Class A common stock (NQ: MRVI - The Chronicle-Journal
Maravai LifeSciences Holdings, Inc. Sued for Securities Law Viola - The National Law Review
Maravai LifeSciences Holdings (MRVI) price target increased by 23.91% to 5.81 - MSN
12 West Capital Amends 13G, Holds 7.26M Shares in Maravai (MRVI) - Stock Titan
Maravai LifeSciences Q1 Turnaround Spurs Rethink Of CleanCap Driven Outlook - Sahm
How The Maravai LifeSciences (MRVI) Narrative Is Shifting With New Targets And 2026 Guidance - Yahoo Finance
Maravai LifeSciences stock (US56600D1072): Q1 turnaround and CleanCap momentum draw fresh investor a - AD HOC NEWS
마라바이 라이프 (MRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
마라바이 라이프 주식 (MRVI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ORESHACK KURT | General Counsel |
Jun 09 '26 |
Sale |
5.06 |
25,000 |
126,500 |
360,767 |
2.60%
0.94%
자본화:
|
볼륨(24시간):